Fortis Hospital, Anandapur has launched the dedicated lung failure clinic, a first-of-its-kind super-specialty outpatient service tailored to patients battling chronic and progressive respiratory ...

Percent-predicted FEV1 measured before pregnancy did not fall 1 year after in women with highly effective cystic fibrosis ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Measles is more than a rash, runny nose and a fever—it can cause brain swelling, blindness and wipe out the immune system's ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...